Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.

Li YD, Lamano JB, Lamano JB, Quaggin-Smith J, Veliceasa D, Kaur G, Biyashev D, Unruh D, Bloch O.

Cancer Immunol Immunother. 2019 Sep;68(9):1501-1513. doi: 10.1007/s00262-019-02384-y. Epub 2019 Sep 5.

PMID:
31489465
2.

Systemic and local immunosuppression in patients with high-grade meningiomas.

Li YD, Veliceasa D, Lamano JB, Lamano JB, Kaur G, Biyashev D, Horbinski CM, Kruser TJ, Bloch O.

Cancer Immunol Immunother. 2019 Jun;68(6):999-1009. doi: 10.1007/s00262-019-02342-8. Epub 2019 Apr 27.

PMID:
31030234
3.

Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases.

Li YD, Lamano JB, Kaur G, Lamano JB, Veliceasa D, Biyashev D, Kruser T, Bloch O.

J Neurooncol. 2019 Jun;143(2):337-347. doi: 10.1007/s11060-019-03169-0. Epub 2019 Apr 13.

PMID:
30982197
4.

Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L, Kesavabhotla K, Kaur R, Kaur G, Biyashev D, Unruh DJ, Horbinski CM, James CD, Parsa AT, Bloch O.

Clin Cancer Res. 2019 Jun 15;25(12):3643-3657. doi: 10.1158/1078-0432.CCR-18-2402. Epub 2019 Mar 1.

PMID:
30824583
5.

The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.

DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, Kaur G, Ampie L, Choy W, Lamano JB, Bloch O.

Oncoimmunology. 2018 Apr 25;7(7):e1448329. doi: 10.1080/2162402X.2018.1448329. eCollection 2018.

6.

Sonic hedgehog delivery from self-assembled nanofiber hydrogels reduces the fibrotic response in models of erectile dysfunction.

Choe S, Veliceasa D, Bond CW, Harrington DA, Stupp SI, McVary KT, Podlasek CA.

Acta Biomater. 2016 Mar 1;32:89-99. doi: 10.1016/j.actbio.2016.01.014. Epub 2016 Jan 14.

7.

Therapeutic manipulation of angiogenesis with miR-27b.

Veliceasa D, Biyashev D, Qin G, Misener S, Mackie AR, Kishore R, Volpert OV.

Vasc Cell. 2015 Jun 24;7:6. doi: 10.1186/s13221-015-0031-1. eCollection 2015.

8.

Chemopreventive apigenin controls UVB-induced cutaneous proliferation and angiogenesis through HuR and thrombospondin-1.

Tong X, Mirzoeva S, Veliceasa D, Bridgeman BB, Fitchev P, Cornwell ML, Crawford SE, Pelling JC, Volpert OV.

Oncotarget. 2014 Nov 30;5(22):11413-27.

9.

miR-200b inhibits prostate cancer EMT, growth and metastasis.

Williams LV, Veliceasa D, Vinokour E, Volpert OV.

PLoS One. 2013 Dec 31;8(12):e83991. doi: 10.1371/journal.pone.0083991. eCollection 2013.

10.

The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?

Craword SE, Fitchev P, Veliceasa D, Volpert OV.

Expert Opin Drug Discov. 2013 Jul;8(7):769-92. doi: 10.1517/17460441.2013.794781. Epub 2013 May 6. Review.

PMID:
23642051
11.

Androgen receptor drives cellular senescence.

Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV.

PLoS One. 2012;7(3):e31052. doi: 10.1371/journal.pone.0031052. Epub 2012 Mar 5.

12.

miR-27b controls venous specification and tip cell fate.

Biyashev D, Veliceasa D, Topczewski J, Topczewska JM, Mizgirev I, Vinokour E, Reddi AL, Licht JD, Revskoy SY, Volpert OV.

Blood. 2012 Mar 15;119(11):2679-87. doi: 10.1182/blood-2011-07-370635. Epub 2011 Dec 29.

13.

Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.

McMahon KM, Mutharasan RK, Tripathy S, Veliceasa D, Bobeica M, Shumaker DK, Luthi AJ, Helfand BT, Ardehali H, Mirkin CA, Volpert O, Thaxton CS.

Nano Lett. 2011 Mar 9;11(3):1208-14. doi: 10.1021/nl1041947. Epub 2011 Feb 14.

14.

Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor gamma (PPARgamma).

Biyashev D, Veliceasa D, Kwiatek A, Sutanto MM, Cohen RN, Volpert OV.

J Biol Chem. 2010 Apr 30;285(18):13517-24. doi: 10.1074/jbc.M110.117374. Epub 2010 Feb 25.

15.

The genome of Beet cryptic virus 1 shows high homology to certain cryptoviruses present in phylogenetically distant hosts.

Szego A, Enünlü N, Deshmukh SD, Veliceasa D, Hunyadi-Gulyás E, Kühne T, Ilyés P, Potyondi L, Medzihradszky K, Lukács N.

Virus Genes. 2010 Apr;40(2):267-76. doi: 10.1007/s11262-009-0432-4.

PMID:
20058060
16.

PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.

Veliceasa D, Schulze-Hoëpfner FT, Volpert OV.

PPAR Res. 2008;2008:945275. doi: 10.1155/2008/945275. Epub 2008 Nov 18.

17.

Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.

Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L, Huang XM, Volpert OV.

J Urol. 2008 Jun;179(6):2427-34. doi: 10.1016/j.juro.2008.01.081. Epub 2008 Apr 23.

18.

Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.

Veliceasa D, Ivanovic M, Hoepfner FT, Thumbikat P, Volpert OV, Smith ND.

FEBS J. 2007 Dec;274(24):6365-77. Epub 2007 Nov 15.

19.

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV.

Int J Cancer. 2007 Sep 1;121(5):999-1008.

20.

Searching for a new putative cryptic virus in Pinus sylvestris L.

Veliceasa D, Enünlü N, Kós PB, Köster S, Beuther E, Morgun B, Deshmukh SD, Lukács N.

Virus Genes. 2006 Apr;32(2):177-86.

PMID:
16604450
21.

MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.

Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB.

Cancer Res. 2005 Dec 1;65(23):10651-6.

22.

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV.

Clin Cancer Res. 2005 Sep 15;11(18):6678-85.

23.

Characterisation of epitopes on barley mild mosaic virus coat protein recognised by a panel of novel monoclonal antibodies.

Veliceasa D, Tauscher G, Surányi G, Kós PB, Likó I, Santore U, Proll E, Ehrig F, Uray K, Hudecz F, Kühne T, Lukács N.

Arch Virol. 2005 Dec;150(12):2501-12. Epub 2005 Jul 14.

PMID:
16012783
24.

Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV.

Cancer Res. 2005 Jun 15;65(12):5144-52.

25.

Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.

Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV.

Mol Cancer Res. 2004 Oct;2(10):541-50.

26.

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.

27.

Dynamics of the HIV-1 variability in adults from Bucharest, 1992-1998.

Chiţu V, Diaconu CC, Veliceasa D, Ruţă S, Grancea C, Târdei G, Cernescu CE.

Rom J Virol. 1999 Jan-Dec;50(1-4):43-51.

PMID:
11601379

Supplemental Content

Loading ...
Support Center